Zobrazeno 1 - 10
of 102
pro vyhledávání: '"Yuko Iida"'
Autor:
Kosei Doshita, Tateaki Naito, Suguru Matsuda, Meiko Morita, Motoki Sekikawa, Keita Miura, Hiroaki Kodama, Michitoshi Yabe, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Haruyasu Murakami, Hirotsugu Kenmotsu, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 15, Iss 25, Pp 1831-1841 (2024)
Abstract Background Chemotherapy‐induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between chemotherapy‐induced anorexia and weight loss during platinum‐based chemothera
Externí odkaz:
https://doaj.org/article/1c619e4840f7419cb18ab6e638421ba1
Autor:
Meiko Morita, Akira Ono, Motoki Sekikawa, Kosei Doshita, Keita Miura, Hiroaki Kodama, Michitoshi Yabe, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Mitsuhiro Isaka, Yasuhisa Ohde, Toshiaki Takahashi
Publikováno v:
Cancer Reports, Vol 7, Iss 9, Pp n/a-n/a (2024)
ABSTRACT Background Mutations in the epidermal growth factor receptor (EGFR) gene are the most common targetable gene alterations in non‐small cell lung cancer (NSCLC). In Japan, approximately 40% of patients who undergo surgical resection for non
Externí odkaz:
https://doaj.org/article/3c7205c59c0848928a7fc40d19564462
Autor:
Yuko Iida, Kazushige Wakuda, Hirotsugu Kenmotsu, Kosei Doshita, Hiroaki Kodama, Naoya Nishioka, Eriko Miyawaki, Taichi Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Akira Ono, Tateaki Naito, Haruyasu Murakami, Takashi Sugino, Yasuhiro Gon, Toshiaki Takahashi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) is unclear. This study aimed to evaluate the efficacy of second-line chemotherapy in patients with pulmonary LCNEC. We retrospect
Externí odkaz:
https://doaj.org/article/9ca57d0b679e413492866893556df8e6
Autor:
Yuko Iida, Kazushige Wakuda, Takuya Kawata, Meiko Morita, Motoki Sekikawa, Kosei Doshita, Michitoshi Yabe, Hiroaki Kodama, Keita Miura, Noboru Morikawa, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Yasuhiro Gon, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 15, Iss 6, Pp 477-485 (2024)
Abstract Background Which patients benefit from the addition of immune checkpoint inhibitors (ICIs) to chemotherapy for small cell lung cancer (SCLC) remains unclear. There have been few reports on the efficacy of ICIs based on conventional immunohis
Externí odkaz:
https://doaj.org/article/e463e71dc180423c8cb17938224f6040
Autor:
Motoki Sekikawa, Haruyasu Murakami, Meiko Morita, Kosei Doshita, Keita Miura, Hiroaki Kodama, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Hirofumi Chiba, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 14, Iss 35, Pp 3475-3482 (2023)
Abstract Background Amrubicin (AMR) regimens have shown efficacy as second‐line treatment in patients with small cell lung cancer (SCLC); however, adverse events such as febrile neutropenia (FN) sometimes preclude their use. Further, the safety and
Externí odkaz:
https://doaj.org/article/4fa201b940bf4f3497e40475cb88b5de
Autor:
Nobuaki Mamesaya, Hiroaki Kodama, Yuko Iida, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Tetsuo Shimizu, Yasuhiro Gon, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 14, Iss 9, Pp 805-814 (2023)
Abstract Carboplatin plus etoposide is a standard treatment for older extensive‐stage small‐cell lung cancer (ES‐SCLC) patients with performance status (PS) 2. However, older patients often exhibit poor PS (3, 4), and the treatment effect in th
Externí odkaz:
https://doaj.org/article/734358fe8024448d9b3af96c47a4f54d
Autor:
Taichi Miyawaki, Hirotsugu Kenmotsu, Kosei Doshita, Hiroaki Kodama, Naoya Nishioka, Yuko Iida, Eriko Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Keita Mori, Hideyuki Harada, Masahiro Endo, Kazuhisa Takahashi, Toshiaki Takahashi
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1451-1460 (2023)
Abstract Background Programmed cell death 1 (PD‐1)/programmed cell death ligand (PD‐L1) inhibitors plus chemotherapy (ICI + Chemo) is the standard treatment for advanced non‐small‐cell lung cancer (NSCLC). However, the impact of tumour burden
Externí odkaz:
https://doaj.org/article/6a37993073c9463ea5acbdf407d85511
Autor:
Yuko Iida, Yoko Nakanishi, Tetsuo Shimizu, Masayuki Nomoto, Yoshiko Nakagawa, Reiko Ito, Noriaki Takahashi, Shinobu Masuda, Yasuhiro Gon
Publikováno v:
Thoracic Cancer, Vol 13, Iss 16, Pp 2362-2370 (2022)
Abstract Background Combined small‐cell lung cancer (cSCLC) is a rare type of small‐cell lung cancer (SCLC) that includes both SCLC and non‐small‐cell lung cancer (NSCLC). The molecular biological mechanisms underlying the heterogeneity of hi
Externí odkaz:
https://doaj.org/article/cc1a90e324c944e5a04fd8827a8327fa
Autor:
Taichi Miyawaki, Tateaki Naito, Kosei Doshita, Hiroaki Kodama, Mikiko Mori, Naoya Nishioka, Yuko Iida, Eriko Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Haruyasu Murakami, Keita Mori, Hideyuki Harada, Masahiro Endo, Kazuhisa Takahashi, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 13, Iss 14, Pp 2064-2074 (2022)
Abstract Background Cancer cachexia and tumor burden predict efficacies of programmed cell death‐1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitors and chemotherapy or pembrolizumab in non‐small cell lung cancer (NSCLC). There are no pre
Externí odkaz:
https://doaj.org/article/055f322f354a4bb88572f00b0542def1
Autor:
Naoya Nishioka, Tateaki Naito, Taichi Miyawaki, Michitoshi Yabe, Kosei Doshita, Hiroaki Kodama, Eriko Miyawaki, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Haruyasu Murakami, Koichi Takayama, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 13, Iss 10, Pp 1496-1504 (2022)
Abstract Background Adipose tissue induces inflammation, which desensitizes the efficacy of immunotherapy. However, several reports show that the therapeutic effect of programed cell death 1 (PD‐1)/programed death‐ligand 1 (PD‐L1) inhibitor(s)
Externí odkaz:
https://doaj.org/article/44faf2ba75f844fd9d2a1ec12c53b599